Abstract: Disclosed is a process for the preparation of rivaroxaban and purifying rivaroxaban.

Abstract: An amorphous form of aprepitant and a process for its preparation is provided. Also provided are mixtures of polymorph Forms I and II of aprepitant and a process for the preparation thereof.

Abstract: The present invention provides process for the preparation of ivacaftor and solvates thereof.

Abstract: The present invention provides a process for the preparation and purification of apixaban.

Abstract: The present invention relates to process for the preparation of tofacitinib and intermediates thereof.

Abstract: The present invention relates to a pre-lyophilized composition comprising bendamustine or its pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, an organic solvent and water. Furthermore, the present invention provides a stable pharmaceutical composition comprising bendamustine hydrochloride prepared from such pre-lyophilized composition, a process for preparing such composition; and its use in the treatment of cancer.

Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

Abstract: The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.

Abstract: The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier, process for preparing such composition, and its use for the treatment of respiratory disorder in a subject.

Abstract: The present invention relates to a stable topical formulation comprising an effective amount of voriconazole or its pharmaceutically acceptable salt, and at least a pharmaceutical carrier; a process for preparing the same and use of such formulation for the treatment of local or non-systemic fungal infections in a subject. In particular, the present invention relates to a stable topical formulation exhibiting a storage stability at a temperature of about 40° C. and a relative humidity of about 75% for a period of at least 3 months, and contains not more than 9% w/w total impurities (based on total weight of the formulation) formed upon storage.

Abstract: A process for preparing a crystalline form of linezolid is provided comprising (a) providing a solution comprising linezolid in an organic solvent having a boiling point of less than or equal to about 150° C.; (b) adding an anti-solvent having a boiling point greater than or equal to about 50° C. to the solution; and (c) recovering the crystalline form of linezolid.

Abstract: The present invention provides a process for the preparation of atovaquone exhibiting characteristic peaks (expressed in degrees 2?±0.2°?) at approximately one or more of the positions: about 7.0, 9.7, 14.2, 14.8, 17.0, 19.2, 20.4, 22.1, 22.7, 26.9 and 28.7, which comprises: (a) providing a solution comprising atovaquone in an aprotic polar solvent; (b) adding a suitable antisolvent to precipitate atovaquone; and (c) isolating the precipitate.

Abstract: A pharmaceutical composition in solid form containing at least a therapeutically effective amount of one or more statins in the free acid form is disclosed.

Abstract: An improved process for the preparation of key intermediates for tazarotene, 4,4-dimethyl-6-ethynylthiochroman, is provided comprising (a) reacting 4,4-dimethyl-6-acetylthiochroman of the formula with an acid chloride and an amido-group containing compound of the general formula wherein R is hydrogen or a hydrocarbyl of from 1 to 15 carbon atoms and R1 and R2 can be the same or different and are hydrocarbyls of from 1 to 15 carbon atoms or R1 and R2 together with the nitrogen atom to which they are bonded are joined together to form a heterocyclic group, optionally containing one or more additional heterocyclic atoms, or one of R1 and R2 together with the nitrogen atom to which it bonded are joined together with the carbonyl radical to form a heterocyclic group, optionally containing one or more additional heterocyclic atoms to form a ?-chloro vinyl carbonyl compound intermediate of the general formula wherein R has the aforestated meanings; and (b) reacting the ?-chloro vinyl carbonyl compound

Abstract: Stable pharmaceutical compositions for oral administration are provided comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, a lactose-based excipient and a pharmaceutically acceptable filler wherein the composition is substantially free of a pharmaceutically acceptable basic salt and wherein the composition contains less than about 1% by weight of N-formyl descarbonylethoxyloratadine after storage at a temperature of from about 25° C. to about 40° C. and a relative humidity of about 60% to about 75% for at least 1 month.

Abstract: Pharmaceutical compositions suitable for the treatment of skin disorder are provided which include at least a therapeutically effective amount of at least on antiacne agent and at least one antibiotic agent as active pharmaceutical ingredients and a hydrophilic matrix capable of providing a constant and uniform release of the active pharmaceutical ingredients.

Abstract: Pharmaceutical topical oil in water type emulsion gels comprising ciclopirox or a pharmaceutically acceptable salt thereof are disclosed.

Abstract: A process for preparing perindopril is provided comprising condensing an N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of formula II: wherein X is a halide with an (2S,3aS,7aS)-2-carboxyperhydroindole of formula III: wherein R is hydrogen or a protecting group.

Abstract: Eprosartan mesylate substantially in an amorphous form is disclosed. A composition comprising eprosartan mesylate in a solid form, wherein at least about 80% by weight of the solid eprosartan mesylate is in an amorphous form is also disclosed. The present invention also provides a process for preparing eprosartan mesylate substantially in an amorphous form by providing a solution of eprosartan mesylate in one or more solvents capable of dissolving the eprosartan mesylate and substantially removing the solvent from the solution.

Abstract: Pregabalin substantially in an amorphous form is disclosed. A composition comprising amorphous pregabalin in a solid form, wherein at least about 80% by weight of the solid is amorphous pregabalin in an amorphous form is also disclosed. The present invention also provides a process for preparing amorphous pregabalin substantially in an amorphous form by providing a solution of amorphous pregabalin in one or more solvents capable of dissolving the pregabalin and substantially removing the solvent from the solution.